Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
SAGE Therapeutics Inc
SAGE
Healthcare
Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of...
postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SAGE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 06, 2024 7:33am
New Press Release - Sage Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sage Therapeutics (SAGE)
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 04, 2024 9:19pm
New Press Release - Sage Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAGE
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 04, 2024 7:04pm
New Press Release - SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 04, 2024 12:13pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation...
read article.
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on May 03, 2024 4:47pm
@ the Bell: TSX powers through to close week higher
Canada’s main stock index inched up on Friday. The only drag on the TSX was a drop in the energy sector while mining led gains.
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 4:47pm
New Press Release - ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 4:47pm
New Press Release - Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 10:02am
New Press Release - An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.Before the market opened on April 17, 2024, Sage issued a...
read article.
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on May 02, 2024 8:22am
Buzz on the Bullboards: The top stocks in energy, mining and EVs
While energy gains propel the TSX, industrials get attention from the EV market and investors navigate another week of mining sector activity.
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 30, 2024 3:43pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
New York, New York--(Newsfile Corp. - April 30, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 28, 2024 9:00am
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
NEW YORK, April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 26, 2024 12:02pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2024 5:16pm
New Press Release - INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws.The...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2024 6:33am
New Press Release - Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by BiogenEncouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024Payor coverage now...
read article.
(90)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 17, 2024 8:00pm
Neurodegenerative Disorder-Focused Sage Therapeutics Stock F
JUST IN: $SAGE Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data | BenzingaWednesday,@Sage Therapeutics Inc@(NASDAQ:SAGE) announced topline results
...more
(90)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 17, 2024 7:30pm
Neutral Recommendation Issued On SAGE By Goldman Sachs
BREAKING NEWS: $SAGE Neutral Recommendation Issued On SAGE By Goldman Sachs2024-04-17 12:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for SAGE on April 17, 2024 10:07AM ET. The
...more
(90)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 17, 2024 7:15pm
SAGE Price Target Alert: $22.00. Issued by Truist Financial
BREAKING NEWS: $SAGE SAGE Price Target Alert: $22.00. Issued by Truist Financial2024-04-17 12:00:02 ET Joon Lee from Truist Financial issued a price target of $22.00 for SAGE on 2024-04-17 10:06:00
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada